156 related articles for article (PubMed ID: 23709173)
1. Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer.
Wouters H; Maatman GA; Van Dijk L; Bouvy ML; Vree R; Van Geffen EC; Nortier JW; Stiggelbout AM
Ann Oncol; 2013 Sep; 24(9):2324-9. PubMed ID: 23709173
[TBL] [Abstract][Full Text] [Related]
2. Primary-care patients' trade-off preferences with regard to antidepressants.
Wouters H; Van Dijk L; Van Geffen EC; Gardarsdottir H; Stiggelbout AM; Bouvy ML
Psychol Med; 2014 Aug; 44(11):2301-8. PubMed ID: 24398071
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy for breast cancer: assessing an array of women's treatment experiences and perceptions, their perceived self-efficacy and nonadherence.
Wouters H; Stiggelbout AM; Bouvy ML; Maatman GA; Van Geffen EC; Vree R; Nortier JW; Van Dijk L
Clin Breast Cancer; 2014 Dec; 14(6):460-467.e2. PubMed ID: 24981234
[TBL] [Abstract][Full Text] [Related]
4. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.
Simon R; Latreille J; Matte C; Desjardins P; Bergeron E
Can J Surg; 2014 Feb; 57(1):26-32. PubMed ID: 24461223
[TBL] [Abstract][Full Text] [Related]
5. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
6. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
[TBL] [Abstract][Full Text] [Related]
7. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
8. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Ziller V; Kalder M; Albert US; Holzhauer W; Ziller M; Wagner U; Hadji P
Ann Oncol; 2009 Mar; 20(3):431-6. PubMed ID: 19150950
[TBL] [Abstract][Full Text] [Related]
10. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ejlertsen B; Jensen MB; Mouridsen HT;
Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541
[TBL] [Abstract][Full Text] [Related]
11. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer.
Bender CM; Gentry AL; Brufsky AM; Casillo FE; Cohen SM; Dailey MM; Donovan HS; Dunbar-Jacob J; Jankowitz RC; Rosenzweig MQ; Sherwood PR; Sereika SM
Oncol Nurs Forum; 2014 May; 41(3):274-85. PubMed ID: 24769592
[TBL] [Abstract][Full Text] [Related]
12. Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence.
Wouters H; van Geffen EC; Baas-Thijssen MC; Krol-Warmerdam EM; Stiggelbout AM; Belitser S; Bouvy ML; van Dijk L
Breast; 2013 Oct; 22(5):661-6. PubMed ID: 23770134
[TBL] [Abstract][Full Text] [Related]
13. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
14. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
Bright EE; Petrie KJ; Partridge AH; Stanton AL
Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
16. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
17. Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence.
Haskins CB; Neuner JM; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
Clin Breast Cancer; 2020 Jun; 20(3):e261-e280. PubMed ID: 32139273
[TBL] [Abstract][Full Text] [Related]
18. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
19. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
20. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
